间变性淋巴瘤激酶抑制疗法用于遗传性神经母细胞瘤 - Suppr

Suppr

超能文献

Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma.

作者信息

Mossé Yaël P, Polkosnik Grace, Pogoriler Jenny, Mattei Peter, States Lisa J, Maris John M

机构信息

Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

出版信息

JCO Precis Oncol. 2025 Apr;9:e2400886. doi: 10.1200/PO-24-00886. Epub 2025 Apr 28.

DOI:10.1200/PO-24-00886

PMID:40294355

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12039971/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3fa/12052086/af17be3f6fd0/po-9-e2400886-g001.jpg

相似文献

Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma.间变性淋巴瘤激酶抑制疗法用于遗传性神经母细胞瘤

JCO Precis Oncol. 2025 Apr;9:e2400886. doi: 10.1200/PO-24-00886. Epub 2025 Apr 28.

Identification of Mutation in Neuroblastoma on the Point of Molecular Heterogeneity.神经母细胞瘤分子异质性研究点的基因突变鉴定。

Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231211138. doi: 10.1177/15330338231211138.

A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.克唑替尼用于复发或难治性间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤的I/II期研究及克唑替尼用于复发或难治性神经母细胞瘤的I期研究：一项多中心单臂开放标签试验的研究方案

Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184.

Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma.克唑替尼导致一名神经母细胞瘤患儿出现糜烂性食管炎。

J Oncol Pharm Pract. 2019 Apr;25(3):724-726. doi: 10.1177/1078155217752537. Epub 2018 Jan 22.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.间变性淋巴瘤激酶的基因组改变可能使肿瘤对间变性淋巴瘤激酶抑制剂敏感。

Cancer Res. 2008 May 1;68(9):3389-95. doi: 10.1158/0008-5472.CAN-07-6186.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.克唑替尼治疗儿童难治性实体瘤或间变大细胞淋巴瘤的安全性和活性：儿童肿瘤学组 1 期联盟研究。

Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.阿来替尼，一种间变性淋巴瘤激酶抑制剂，可消除ALK阳性神经母细胞瘤细胞中的ALK活性并抑制其生长。

Front Oncol. 2019 Jul 5;9:579. doi: 10.3389/fonc.2019.00579. eCollection 2019.

Targeting anaplastic lymphoma kinase in neuroblastoma.靶向神经母细胞瘤中的间变性淋巴瘤激酶

APMIS. 2019 May;127(5):288-302. doi: 10.1111/apm.12940. Epub 2019 Apr 3.

The role of anaplastic lymphoma kinase in pediatric cancers.间变性淋巴瘤激酶在儿童癌症中的作用。

Cancer Sci. 2017 Oct;108(10):1913-1920. doi: 10.1111/cas.13333. Epub 2017 Aug 24.

Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.间变性淋巴瘤激酶作为治疗间变大细胞淋巴瘤、非小细胞肺癌和神经母细胞瘤的靶点。

Anticancer Agents Med Chem. 2010 Mar;10(3):236-49. doi: 10.2174/1871520611009030236.

本文引用的文献

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.高危神经母细胞瘤诊断时克隆性和亚克隆性驱动突变的频率及临床意义：一项儿童肿瘤学组研究

J Clin Oncol. 2025 May 10;43(14):1673-1684. doi: 10.1200/JCO-24-02407. Epub 2025 Mar 4.

Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancy.肺癌驱动基因治疗、生育力和妊娠。

J Thorac Oncol. 2024 Jun;19(6):866-876. doi: 10.1016/j.jtho.2024.01.003. Epub 2024 Jan 6.

Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.神经母细胞瘤患者中的胚系致病性变异体在 BARD1 中富集，并预测预后更差。

J Natl Cancer Inst. 2024 Jan 10;116(1):149-159. doi: 10.1093/jnci/djad183.

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.循环肿瘤 DNA 揭示了复发/难治性 ALK 驱动神经母细胞瘤患者对 lorlatinib 耐药的机制。

Nat Commun. 2023 May 5;14(1):2601. doi: 10.1038/s41467-023-38195-0.

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.ALK 驱动型难治/复发神经母细胞瘤中 lorlatinib 联合或不联合化疗的疗效：一项 I 期临床试验结果。

Nat Med. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3.

Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.循环肿瘤 DNA 序列分析鉴定高危神经母细胞瘤中临床可操作基因组改变的动态演变。

Cancer Discov. 2022 Dec 2;12(12):2800-2819. doi: 10.1158/2159-8290.CD-22-0287.

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic -Rearranged NSCLC: A Case Report.阿来替尼治疗转移性重排非小细胞肺癌女性患者的两次非复杂性妊娠：一例报告

JTO Clin Res Rep. 2022 Jun 18;3(8):100361. doi: 10.1016/j.jtocrr.2022.100361. eCollection 2022 Aug.

First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.首例艾乐替尼治疗间变性淋巴瘤激酶重排阳性转移性肺癌患者妊娠的病例报告

J Thorac Oncol. 2021 May;16(5):873-877. doi: 10.1016/j.jtho.2021.02.005. Epub 2021 Mar 30.

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.采用基于反应和生物学的疗法治疗中危神经母细胞瘤以保持优异的疗效：来自儿童肿瘤学组研究 ANBL0531 的报告。

J Clin Oncol. 2019 Dec 1;37(34):3243-3255. doi: 10.1200/JCO.19.00919. Epub 2019 Aug 6.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.基于全身磁共振成像的 Li-Fraumeni 综合征的基线监测：一项荟萃分析。

JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验